Artract Medical develops a percutaneously implanted passive hemodynamic assist device for patients with heart failure with preserved ejection fraction (HFpEF). The Artract System lowers left atrial pressure, enhancing ventricular filling and stroke volume to improve breathing, exercise tolerance, and reduce hospitalizations. The device operates without an external power source or motor, simplifying implantation and long‑term use.
Funding
Funding not disclosed
Founders
Product
Problem
Heart Failure with preserved Ejection Fraction (HFpEF) affects millions worldwide, yet there is a lack of effective medical devices to treat it. Patients experience symptoms like shortness of breath, fatigue, and swollen limbs, leading to frequent hospital admissions and a poor quality of life. The absence of targeted therapies results in a significant socio-economic burden, with high healthcare costs and reduced patient survival rates.
Solution
Artract Medical has developed the Artract System, a percutaneously implanted passive hemodynamic assist device designed specifically for treating HFpEF. The device reduces left atrial blood pressure, alleviating symptoms such as shortness of breath and improving exercise tolerance. By optimizing heart chamber filling and stroke volume, the Artract System aims to improve patients' quality of life, increase life expectancy, and reduce the need for hospital readmissions. The device's passive design eliminates the need for an external energy source or motor, simplifying the implantation procedure and reducing potential complications.
Target Audience
The primary target audience includes patients diagnosed with Heart Failure with preserved Ejection Fraction (HFpEF) who are seeking a minimally invasive treatment option to improve their symptoms and quality of life.
Features
- Percutaneous implantation for minimally invasive placement.
- Passive hemodynamic assist mechanism requiring no external power.
- Reduction of left atrial blood pressure to alleviate HFpEF symptoms.
- Improvement of heart chamber filling and stroke volume.
- Designed to improve exercise tolerance and overall quality of life.
- Aims to reduce hospital admissions associated with HFpEF.